bluuebunny/crossref_metadata_2025_split huggingface dataset:
Removal of Cr(VI) by Zero‐valent, Iron‐encapsulated Alginate Beads
Authors: Wang Xue Song , Tang Yu Jun , Chen Li Fang , Li Fei Yan , Wan Wen Ya , Tan Ye Bin 
Published: March 2010

AbstractZero‐valent, iron‐encapsulated alginate beads were synthesized and were applied for the removal of Cr(VI) from aqueous solutions. The effects of several important parameters including solution pH, contact time, initial concentration and reaction temperature on Cr(VI) removal levels were investigated in batch studies. An initial solution pH of 1.0 was seen to be most favorable for Cr(VI) removal. The removal process was quick and almost 80% of the removal was attained within 60 min. The kinetic data followed the second‐order equation well. The Cr(VI) removal was almost reaction temperature‐independent and decreased with an increase in Cr(VI) initial concentration. The removal of Cr(VI) by iron‐encapsulated alginate beads was found to be significantly higher than that of non‐encapsulated alginate beads.
Prostate cancer‐specific mortality and the extent of therapy in healthy elderly men with high‐risk prostate cancer
Authors: Hoffman Karen E. , Chen Ming‐Hui , Moran Brian J. , Braccioforte Michelle H. , Dosoretz Daniel , Salenius Sharon , Katin Michael J. , Ross Rudi , D'Amico Anthony V. 
Published: March 2010

AbstractBACKGROUND:The risk of prostate cancer‐specific mortality (PCSM) in healthy elderly men may depend on extent of treatment. The authors of this report compared the use of brachytherapy alone with combined brachytherapy, external‐beam radiation to the prostate and seminal vesicles, and androgen‐suppression therapy (CMT) in this population.METHODS:The study cohort comprised 764 men aged ≥65 years with high‐risk prostate cancer (T3 or T4N0M0, prostate‐specific antigen >20 ng/mL, and/or Gleason score 8‐10) who received either brachytherapy alone (n = 206) or CMT (n = 558) at the Chicago Prostate Cancer Center or at a 21st Century Oncology facility. Men either had no history of myocardial infarction (MI) or had a history of MI treated with a stent or surgical intervention. Fine and Gray regression analysis was used to identify the factors associated with PCSM.RESULTS:The median patient age was 73 years (interquartile range, 70‐77 years). After a median follow‐up of 4.9 years, 25 men died of prostate cancer. After adjusting for age and prostate cancer prognostic factors, the risk of PCSM was significantly less (adjusted hazard ratio, 0.29; 95% confidence interval, 0.12‐0.68; P = .004) for men who received CMT than for men who received brachytherapy alone. Other factors that were associated significantly with an increased risk of PCSM included a Gleason score of 8 to 10 (P = .017).CONCLUSIONS:Elderly men who had high‐risk prostate cancer without cardiovascular disease or with surgically corrected cardiovascular disease had a lower risk of PCSM when they received CMT than when they received brachytherapy alone. These results support aggressive locoregional treatment in healthy elderly men with high‐risk prostate cancer. Cancer 2010. © 2010 American Cancer Society.
Patterns of care for early stage bladder cancer
Authors: Strope Seth A. , Ye Zaojun , Hollingsworth John M. , Hollenbeck Brent K. 
Published: March 2010

AbstractBACKGROUND:Early stage bladder cancer is a heterogeneous disease with a variable risk of progression and mortality. Uncertainty surrounding the optimal care for these patients may result in a mismatch between disease risk and treatment intensity.METHODS:Using Surveillance, Epidemiology, End Results‐Medicare data, we identified patients diagnosed with early stage bladder cancer (n = 24,980) between 1993 and 2002. We measured patients' treatment intensity by totaling all Medicare payments made for bladder cancer in the 2 years after diagnosis. Using multiple logistic regression, we assessed relationships between clinical characteristics and treatment intensity. Finally, we determined the extent to which a patient's disease risk matched with their treatment intensity.RESULTS:The average per capita expenditures increased from $6,936 to $7,642 over the study period (10.2% increase; P < .01). This increase was driven by greater use of intravesical therapy (2.6 vs 3.7 instillations per capita, P < .01) and physician office visits (3.0 vs 4.8 visits per capita, P < .01). Generally, treatment intensity was appropriately aligned with many clinical characteristics, including age, comorbidity, tumor stage, and grade. However, treatment intensity matched disease risk for only 55% and 49% of the lowest and highest risk patients, respectively.CONCLUSIONS:The initial treatment intensity of early stage bladder cancer is increasing, primarily through greater use of intravesical therapy and office visits. Treatment intensity matches disease risk for many, but up to 1 in 5 patients may receive too much or too little care, suggesting opportunities for improvement. Cancer 2010. © 2010 American Cancer Society.
Cervical cancer prevention
Authors: Scarinci Isabel C. , Garcia Francisco A.R. , Kobetz Erin , Partridge Edward E. , Brandt Heather M. , Bell Maria C. , Dignan Mark , Ma Grace X. , Daye Jane L. , Castle Philip E. 
Published: March 2010

AbstractCervical cancer is the second most common female tumor worldwide, and its incidence is disproportionately high (>80%) in the developing world. In the United States, in which Papanicolaou (Pap) tests have reduced the annual incidence to approximately 11,000 cervical cancers, >60% of cases are reported to occur in medically underserved populations as part of a complex of diseases linked to poverty, race/ethnicity, and/or health disparities. Because carcinogenic human papillomavirus (HPV) infections cause virtually all cervical cancer, 2 new approaches for cervical cancer prevention have emerged: 1) HPV vaccination to prevent infections in younger women (aged ≤18 years) and 2) carcinogenic HPV detection in older women (aged ≥30 years). Together, HPV vaccination and testing, if used in an age‐appropriate manner, have the potential to transform cervical cancer prevention, particularly among underserved populations. Nevertheless, significant barriers of access, acceptability, and adoption to any cervical cancer prevention strategy remain. Without understanding and addressing these obstacles, these promising new tools for cervical cancer prevention may be futile. In the current study, the delivery of cervical cancer prevention strategies to these US populations that experience a high cervical cancer burden (African‐American women in South Carolina, Alabama, and Mississippi; Haitian immigrant women in Miami; Hispanic women in the US‐Mexico Border; Sioux/Native American women in the Northern Plains; white women in the Appalachia; and Vietnamese‐American women in Pennsylvania and New Jersey) is reviewed. The goal was to inform future research and outreach efforts to reduce the burden of cervical cancer in underserved populations. Cancer 2010. © 2010 American Cancer Society.
Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance
Authors: Kantarjian Hagop , Coutre Phillipp le , Cortes Jorge , Pinilla‐Ibarz Javier , Nagler Arnon , Hochhaus Andreas , Kimura Shinya , Ottmann Oliver 
Published: March 2010

AbstractBACKGROUND:INNO‐406, a dual v‐abl Abelson murine leukemia viral oncogene homolog (Abl)/v‐yes‐1 Yamaguchi sarcoma viral‐related oncogene homolog (Lyn) tyrosine kinase inhibitor (TKI), has demonstrated specific Lyn kinase inhibitory activity with no or limited activity against other sarcoma (Src) family member kinases. Several breakpoint cluster region (Bcr)‐Abl kinase domain mutations are sensitive to INNO‐406 in vitro, including mutations that involve a phenylalanine‐to‐leucine or phenylalanine‐to‐valine substitution at codon 317 (F317L and F317V, respectively). In the current study, the authors evaluated the use of INNO‐406 in patients with Philadelphia (Ph) chromosome‐positive chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) after imatinib resistance or intolerance.METHODS:A dose‐escalation study was conducted at a starting dose of oral INNO‐406 30 mg once daily. Cohorts of at least 3 patients were treated at each dose level until the maximum tolerated dose (MTD) was reached. Twice‐daily dosing also was evaluated. Therapy was allowed to continue for a maximum of 24 months.RESULTS:INNO‐406 was administered to 56 patients with imatinib resistance (n = 40) or intolerance (n = 16). Other previous treatments included nilotinib (n = 20 patients), dasatinib (n = 26 patients), and dasatinib/nilotinib (n = 9 patients). Common mutations at the time of study entry included a tyrosine‐to‐histidine substitution at codon 253 (Y253H) (n = 6 patients), a glycine‐to‐glutamic acid substitution at codon 250 (G250E) (n = 4 patients), a threonine‐to‐isoleucine substitution at codon 315 (T315I) (n = 4 patients), and F317L (n = 3 patients). Of 31 patients with CML in chronic phase who received INNO‐406, the major cytogenetic response rate was 19%. No responses were observed in patients who had CML in accelerated phase, CML in blastic phase, or Ph‐positive ALL. The dose‐limiting toxicities (DLTs) at an INNO‐406 dose of 480 mg twice daily were liver function abnormalities and thrombocytopenia.CONCLUSIONS:INNO‐406 had anti‐CML efficacy in a heavily pretreated study population. On the basis of the classic determinations of both DLT and MTD, the recommended phase 2 dose of oral INNO‐406 was 240 mg twice daily. Lower doses of INNO‐406 may be equally effective and should be explored. Cancer 2010. © 2010 American Cancer Society.
Race versus place of service in mortality among Medicare beneficiaries with cancer
Authors: Onega Tracy , Duell Eric J. , Shi Xun , Demidenko Eugene , Goodman David C. 
Published: March 2010

AbstractBACKGROUND:Evidence suggests that excess mortality among African‐American cancer patients is explained in part by the healthcare setting. The objective of this study was to compare mortality among African‐American and Caucasian cancer patients and to evaluate the influence of attendance at a National Cancer Institute (NCI)‐designated comprehensive or clinical cancer center.METHODS:The authors conducted a retrospective cohort analysis of Medicare beneficiaries with an incident diagnosis of lung, breast, colorectal, or prostate cancer between 1998 and 2002 who were identified from Surveillance, Epidemiology, and End Results data. Multivariate logistic regression models were used to assess the impact of NCI cancer center attendance and race on all‐cause and cancer‐specific mortality at 1 year and 3 years after diagnosis.RESULTS:The likelihood of 1‐year and 3‐year all‐cause and cancer‐specific mortality was higher for African Americans than for Caucasians in crude and adjusted models (cancer‐specific adjusted: Caucasian referent, 1‐year odds ratio [OR], 1.13; 95% confidence interval [CI], 1.07‐1.19; 3‐year OR, 1.23; 95% CI, 1.17‐1.30). By cancer site, cancer‐specific mortality was higher among African Americans at 1 year for breast and colorectal cancers and for all cancers at 3 years. NCI cancer center attendance was associated with significantly lower odds of mortality for African Americans (1‐year OR, 0.63; 95% CI, 0.56‐0.76; 3‐year OR, 0.71; 95% CI, 0.62‐0.81). With Caucasians as the referent group, the excess mortality risk among African Americans no longer was observed for all‐cause or cancer‐specific mortality risk among patients who attended NCI cancer centers (cancer‐specific mortality:1‐year OR, 0.95; 95% CI, 0.76‐1.19; 3‐year OR, 1.00; 95% CI, 0.82‐1.21).CONCLUSIONS:African‐American Medicare beneficiaries with lung, breast, colorectal, and prostate cancers had higher mortality compared with their Caucasian counterparts; however, there were no significant differences in mortality by race among those who attended NCI cancer centers. The results of this study suggested that place of service may explain some of the cancer mortality excess observed in African Americans. Cancer 2010. © 2010 American Cancer Society.
Corporate response to CSO criticism: decoupling the corporate responsibility discourse from business practice
Authors: Ählström Jenny 
Published: March 2010

AbstractThe general objective of this paper is to further research on the interaction between civil society organizations (CSOs) and corporations. The aim is to analyze how corporations are responding to demands to enlarge the responsibility sphere. A case is presented in which CSOs are putting pressure on the garment retailer Hennes & Mauritz (H&M) to be responsible for safeguarding workers' rights in the outsourced production of H&M garments. The conclusion of the paper, derived from analyzing the empirical context using discourse theory, is that: (1) CSOs represent a challenging discourse (responsible business) attempting to change the dominant corporate discourse (profitable business); (2) If the challenging discourse is threatening the legitimacy of the corporation, a responsible business discourse is created; and (3) Responding to the demands of the CSOs is done to keep the business practice intact, hence practice is decoupled from the responsible business discourse. Copyright © 2010 John Wiley & Sons, Ltd and ERP Environment.
Improved control‐to‐output characteristics of a PWM buck‐boost converter
Authors: Lo Yu‐Kang , Chen Jun‐Ting , Lin Chung‐Yi , Ou Sheng‐Yuan 
Published: March 2010

AbstractAn indirect control variable for improving the control‐to‐output characteristics of a Pulse Width Modulation (PWM) buck‐boost converter is introduced in this letter. The voltage gain and the small‐signal model of the buck‐boost converter are reviewed. The actual voltage command at one input of the PWM comparator is from the proposed indirect control variable and the peak value of the high‐frequency PWM carrier. The resulted voltage gain function appears proportional to this indirect control command. Also the dependence of the DC gain of the control‐to‐output transfer function on the duty cycle is eliminated. Experimental results conform well to the theoretical analysis. Copyright © 2010 John Wiley & Sons, Ltd.
Non‐invasive chaos control of DC–DC converter and its optimization
Authors: Wei‐Guo Lu , Luo‐Wei Zhou , Quan‐Ming Luo , Jun‐Ke Wu 
Published: March 2010

AbstractThe frequency‐domain‐based realization condition related to a novel non‐invasive chaos control is presented in this paper. According to the common piecewise‐linear characteristics of PWM‐controlled DC–DC converter system, a general expression for its Jacobian matrix is derived for optimizing the control parameters of the proposed non‐invasive chaos control. The relevant simulation and experiment results about the application of the chaos control to a voltage‐mode Buck converter are given, which confirm the feasibility of the parameter‐optimization method and the validity of the proposed non‐invasive chaos control. Copyright © 2010 John Wiley & Sons, Ltd.
Calculation of steady‐state solution of parallel‐connected buck converters with active current sharing and its parameter sensitivity
Authors: Li Ming , Tse Chi K. , Ma Xikui 
Published: March 2010

AbstractIn this paper, the effect of active current‐sharing control on the steady‐state operation of parallel‐connected buck converters is investigated. The system under study consists ofNvoltage‐mode‐controlled buck converters connected in parallel. Three kinds of active current‐sharing schemes are considered, namely, master–slave scheme with automatic master, master–slave scheme with dedicated master, and democratic scheme. Using the principle of charge balance, the mechanism of the operating point drift arising from active current sharing is examined. A general formulation of the steady‐state solution under active current sharing is derived. Moreover, detailed parameter sensitivity analysis is performed to evaluate the effect of parameters' variation on the operating point. The results from sensitivity analysis can be used to categorize parameters for facilitating practical design. Computer simulations are presented to verify the analytical results. Copyright © 2010 John Wiley & Sons, Ltd.
The relation of Tellegen's theorem to the continuous field equations revisited
Authors: Jakoby B. 
Published: March 2010

AbstractTellegen's theorem for networks is directly derived from Maywell's equations. As for general circuits including capacitors and inductances, non‐vanishing displacement currents and temporally varying magnetic fluxes are present, in the presented approach domains containing lumped elements are treated such that the utilization of an electric potential and of Kirchhoff's current law can be maintained in the considered field domain. The procedure works for the general form of Tellegen's theorem including nonlinear elements and relating topologically equal but otherwise different networks. Copyright © 2010 John Wiley & Sons, Ltd.
Generation of Kerwin‐Huelsman‐Newcomb biquad filter circuits using nodal admittance matrix expansion
Authors: Soliman Ahmed M. 
Published: March 2010

AbstractNodal admittance matrix (NAM) expansion is used to generate a family of grounded passive component Kerwin Huelsman Newcomb (KHN) circuits. The generated KHN circuits have independent control on the selectivity factor and the radian frequency as in the original KHN, besides they have independent control on the gain, which is not achievable in the original KHN circuit. The NAM expansion is based on using nullor elements and voltage mirror and current mirror as well. Two types of the KHN circuit are considered, each includes four classes. For each class it is found that there are 32 different KHN circuit; therefore, there is a total of 128 circuits that belong to type‐A KHN and a similar number for type‐B KHN circuits. Simulation results are included to support the generation method. Copyright © 2010 John Wiley & Sons, Ltd.
Square‐root domain linear transformation filters
Authors: Stoumpou Eleni , Psychalinos Costas 
Published: March 2010

AbstractA new systematic method for designing square‐root domain (SRD) linear transformation (LT) filter is introduced in this paper. For this purpose, a substitution table containing the SRD LT equivalent of each passive element has been introduced. The proposed equivalents have been realized by employing appropriate SRD building blocks with low‐voltage operation capability. As a design example, a 3rd‐order SRD LT filter has been realized and its performance has been evaluated through simulation results. In addition, the most important performance factors of the SRD filter have been compared with those achieved by the SRD filters derived according to the leapfrog, wave, and topological emulation methods. Copyright © 2010 John Wiley & Sons, Ltd.
Deposition of Bio‐Integration Ceramic Hydroxyapatite by Pulsed‐Pressure MOCVD Using a Single Liquid Precursor Solution
Authors: Krumdieck Susan P. , Reyngoud Benjamin P. , Barnett Anne D. , Clearwater Deborah J. , Hartshorn Richard M. , Bishop Catherine M. , Redwood Benjamin P. , Palmer Ellen L. 
Published: March 2010

AbstractPulsed‐pressure (PP) metal‐organic(MO)CVD is used to deposit layers of calcium phosphate onto flat bio‐medical grade titanium (Ti6Al4V) substrates. Inexpensive calcium lactate and trimethyl phosphate (TMP), combined in a methanol solution, forms the precursor. A range of precursor mixtures is studied by thermogravimetric analysis (TGA) to assess reaction pathways. The surface topography, morphology, composition, and crystallinity are studied over a range of deposition temperatures and precursor concentrations. The resulting films are analyzed by scanning electron microscopy (SEM), energy dispersive spectroscopy (EDS), X‐ray diffraction (XRD), Raman spectroscopy (RS), and micro‐indentation. The films are continuous and the size of surface structures increases at higher temperatures and precursor concentration. The films consist of amorphous calcium phosphate in elemental Ca/P ratios similar to the standard bio‐ceramic, hydroxyapatite (1.66).
Enumeration of the absolute CD4 T‐lymphocyte count by cell‐bead assay
Authors: Nantakomol Duangdao , Nuchnoi Pornlada , Noulsri Egarit , Lerdwana Surada , Krisin Sririma , Chanprasert Supantitra , Pattanapanyasat Kovit 
Published: March 2010

AbstractBackground:We have previously developed an alternative approach for undertaking absolute cell counting based upon flow‐rate calibration using cell bead (FCB), in which cell bead (CB) can be used as a flow‐rate calibration material for generating the absolute microparticle counts. Here, we extended our work of counting CD4+ T‐lymphocytes in HIV‐infected blood samples with the FCB method.Methods:CD4+ T‐lymphocyte counts in EDTA blood samples from 30 healthy subjects and 80 HIV‐1‐infected patients were determined using TriTEST reagent. The absolute CD4+ T‐lymphocytes were measured by FCB, and the results were compared with the absolute counting by commercial latex bead (CLB) or with flow rate‐based calibration method (FR). Statistical correlation and agreement were analyzed using linear regression and Bland–Altman analysis.Results:There was no significant difference in the absolute number of CD4+ T‐lymphocyte counts enumerated by FCB when compared with those two reference methods (CLB and FR). The absolute CD4+ T‐lymphocyte counts obtained from FCB method was highly correlated with those obtained from CLB [r2= 0.99, y = 1.04x − 12.37, P < 0.001, and mean bias 11.96 cell/μl, limit of agreement (LOA) −57.82 – 81.74 cell/μl], FR method (r2 = 0.98; y = 0.97x − 3.13, P < 0.001, and mean bias −24.15 cell/μl, LOA −114.44 − 66.13 cell/μl).Conclusions:The use of FCB is comparable with the use of CLB and FR. This approach showed the effective in reducing cost for generating the absolute CD4+ T‐lymphocyte counts. Such an approach should facilitate and ensure the success of the ongoing antiretroviral therapy program in resource‐limited countries. © 2010 Clinical Cytometry Society
Econazole‐induced Ca2+ fluxes and apoptosis in human oral cancer cells
Authors: Kuo Daih‐Huang , Liu Li‐Min , Chen Hsin‐Wei , Chen Fu‐An , Jan Chung‐Ren 
Published: March 2010

AbstractThe effect of econazole on cytosolic free Ca2+ concentrations ([Ca2+]i) and viability was explored in human oral cancer cells (OC2), using the fluorescent dyes fura‐2 and WST‐1, respectively. Econazole at concentrations of >1 µM increased [Ca2+]i in a concentration‐dependent manner. The Ca2+ signal was reduced partly by removing extracellular Ca2+. The econazole‐induced Ca2+ influx was sensitive to blockade of aristolochic acid (phospholipase A2 inhibitor) and GF109203X (PKC inhibitor). In Ca2+‐free medium, after treatment with 1 µM thapsigargin (an endoplasmic reticulum Ca2+ pump inhibitor), 30 µM econazole failed to induce a [Ca2+]i rise. Inhibition of phospholipase C with 2 µM U73122 substantially suppressed econazole‐induced [Ca2+]i rise. At concentrations of 5–70 µM econazole killed cells in a concentration‐dependent manner. The cytotoxic effect of 50 µM econazole was enhanced by prechelating cytosolic Ca2+ with 1,2‐bis(2‐aminophenoxy)ethane‐N,N,N′,N′‐tetraacetic acid (BAPTA). The ERK MAPK inhibitor, PD98059 (10 µM), also enhanced 20 µM econazole‐induced cell death. Propidium iodide staining data suggest that econazole induced apoptosis between concentrations of 10–70 µM. Collectively, in OC2 cells, econazole induced [Ca2+]i rises by causing Ca2+ release from the endoplasmic reticulum and Ca2+ influx from phospholipase A2/PKC‐regulated Ca2+ channels. Furthermore, econazole caused cell death appeared to be regulated by ERK MAPK. Drug Dev Res 71: 240–248, 2010. © 2010 Wiley‐Liss, Inc.